We use cookies to understand how visitors search for and consume the information we provide, so that we can improve their experience. By browsing this website, you indicate your acceptance of the use of such cookies
Accept
Read more
Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Our products
& pipeline
Diseases we target
GS010 for LHON
GS030 for Retinitis Pigmentosa
GS030 for Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Investors
& media
Company Overview
Press releases
Events & presentations
Stock information
Governance
Documentation
Product candidates
Year
All
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
Company and personnel
GS010
GS030
Technologies
Other
13 Nov 2020 - 15 Nov 2020
American Academy of Ophthalmology 2020 – Virtual
03 November 2020
GenSight Biologics reports validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency
06 Nov 2020
Eyecelerator 2020 – Virtual Conference
02 Nov 2020 - 05 Nov 2020
World Orphan Drug Congress Europe 2020 – Live Digital
26 Oct 2020 - 29 Oct 2020
BioEurope – Digital
26 Oct 2020 - 28 Oct 2020
4th Annual Gene Therapy for Rare Disorders Europe – Virtual
12 Oct 2020 - 16 Oct 2020
Cell & Gene Meeting on the Mesa – Virtual
02 Oct 2020 - 04 Oct 2020
EURETINA 2020 – Virtual
30 Sep 2020
Ophthalmology Futures Retina – Virtual Forum
28 September 2020
GenSight Biologics Announces Publication of Meta-Analysis Confirming that Spontaneous Recovery in LHON is rare in the Journal of Neuro-Ophthalmology
1
2
3
4
5
6
…
9
View next 9 articles
Go back to the page of the page
